Safety of sorafenib (SOR) dose in United States (US) patients (pts) with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction: Lessons from a Hispanic-rich South Texas institution.

Sukeshi R Patel,Joel Michalek,Ting-Wei Lu,Norma S Ketchum,Raed Moh'D Taiseer Al-Rajabi,Devalingam Mahalingam

doi:10.1200/jco.2015.33.15_suppl.e15150

Safety of sorafenib (SOR) dose in United States (US) patients (pts) with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction: Lessons from a Hispanic-rich South Texas institution.

Sukeshi R Patel, Joel Michalek + Show 4 more

https://doi.org/10.1200/jco.2015.33.15_suppl.e15150

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2015

Affiliation: The University of Texas Health Science Center at San Antonio

#Hepatocellular Carcinoma Pts #Child Pugh + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

e15150 Background: HCC pts often present with Child Pugh (CP) B liver dysfunction but are poorly represented in trials. GIDEON showed median dose (duration) was 742 mg (17.6 weeks) in CP A vs 677 m...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.